NSCLC Burden of Illness Study (LuCaBIS)
A Burden-of Illness Study in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)
Sponsor: GlaxoSmithKline
Listed as NCT01772225, this observational or N/A phase trial focuses on Lung Cancer, Non-Small Cell and remains completed. Sponsored by GlaxoSmithKline, it has been updated 6 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
▶ Show 1 earlier version
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Sep 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- RTI Health Solutions
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.